A REVIEW OF TRASTUZUMAB SEQUENCE

Probably the most beneath-investigated “driving forces” involved in trastuzumab resistance is PTEN. Nagata et al. (2004) described that the lack of PTEN was observed in 36% of HER2-favourable Most important breast tumor specimens from clients with stage IV disease. Moreover, they also confirmed that clients with PTEN-deficient tumors experience